Wegovy (semaglutide 2.4 mg) is a once-weekly injection licensed for weight management in adults with obesity or overweight with comorbidities
The product was removed from refrigerated storage for an extended period of time.Recall Initiation Date: April 9, 2025Link: FDA Enforcement Report Facility Inspections FDA Warning Letters ProRx, LLC Type: Compounding pharmacy and FDA-registered outsourcing facilityFDA Department issuing Warning: Center for Drug Evaluation and Research (CDER)Warning Letter Date: January 15, 2025Facility Location: Exton, PennsylvaniaInspection Dates: July 15, 2024, to August 2, 2024
Mechanism of glycemic control GLP-1, a natural hormone, plays a fundamental role in governing blood glucose levels
Martinez DR, Schafer A, Gavitt TD, Mallory ML, Lee E, Catanzaro NJ, et al
Semaglutide base is the active ingredient in the FDA-approved formulations, Ozempic and Wegovy
The effect of asparaginase can largely be reversed through the reintroduction of small amounts of glutamine [92]
